This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by FLEISCHHACKER, W.W.
Right arrow Articles by MEHNERT, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FLEISCHHACKER, W.W.
Right arrow Articles by MEHNERT, A.
The British Journal of Psychiatry (2005) 187: 131-136
© 2005 The Royal College of Psychiatrists

Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year

W.WOLFGANG FLEISCHHACKER, MD

Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria

JONATHAN RABINOWITZ, PhD

Bar Ilan University, Ramat Gan, Israel

GEORG KEMMLER, PhD

Department of Biological Psychiatry, Medical University Innsbruck, Austria

MARIëLLE EERDEKENS, MD

Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium

ANGELIKA MEHNERT, PhD

Janssen-Cilag GmbH Department for Health Economics, Neuss, Germany

Correspondence: Professor W.W. Fleischhacker, Department of Biological Psychiatry, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. Tel: +43 (512) 504 23669; fax: +43 (512) 504 25267; e-mail: wolfgang.fleischhacker{at}uibk.ac.at

Declaration of interest W.W.F. has received research support, consultancy honoraria and fees from Astra Zeneca, BMS, Eli Lilly, Janssen, Otsuka, Pfizer and Sanofi Synthelabo. J.R. has received honoraria and travel support from Johnson and Johnson and other manufacturers of antipsychotics. G.K. has received research support from Janssen.M.E. is an employee of Johnson and Johnson, Belgium and A.M. of Janssen-Cilag, Germany.

Background The extent to which antipsychotics improve patients' well-being is uncertain.

Aims To examine psychopathology and patient-rated functioning and well-being in patients treated with risperidone.

Method In a 1-year, open-label, international multicentre trial of long-acting risperidone in 615 stable adult patients with schizophrenia, self-rated functioning and well-being were measured every 3 months using the Short Form 36-item questionnaire (SF-36). Psychopathology was quantified using the Positive and Negative Syndrome Scale (PANSS).

Results Significant improvements were found on the SF-36 mental component summary score and vitality and social functioning scales. PANSS and mental component summary scores were moderately correlated.

Conclusions Patient-reported functioning and well-being appear to differ from investigator-rated psychotic symptoms. Patient-rated well-being should be assessed with symptoms to help measure treatment outcomes.


Related articles in BJP:

Highlights of this issue
KIMBERLIE DEAN
BJP 2005 187: 101-a5. [Full Text]  



This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
W. W. Fleischhacker
Second-generation antipsychotic long-acting injections: systematic review
The British Journal of Psychiatry, November 1, 2009; 195(52): S29 - S36.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
R. McCabe, M. Saidi, and S. Priebe
Patient-reported outcomes in schizophrenia
The British Journal of Psychiatry, August 1, 2007; 191(50): s21 - s28.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
E. Bromley
Barriers to the Appropriate Clinical Use of Medications That Improve the Cognitive Deficits of Schizophrenia
Psychiatr Serv, April 1, 2007; 58(4): 475 - 481.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
S. Burton
Symptom domains of schizophrenia: the role of atypical antipsychotic agents
J Psychopharmacol, November 1, 2006; 20(6_suppl): 6 - 19.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
P. Chue
The relationship between patient satisfaction and treatment outcomes in schizophrenia
J Psychopharmacol, November 1, 2006; 20(6_suppl): 38 - 56.
[Abstract] [PDF]